Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.64, $0.03 better than the analyst estimate of $0.61. Revenue for the quarter came in at $1.35 billion versus the consensus estimate of $1.33 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.